Emerging drugs to treat Crohn's disease

Expert Opinion on Emerging Drugs

Volumn 12, Issue 1, 2007, Pages 49-59

  Van Assche, Gert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biologic treatment; Controlled trial; Crohn's disease; Inflammatory bowel disease; Medical treatment

Indexed keywords

ABT 874; ADALIMUMAB; ALICAFORSEN; ATLIZUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CNTO 1275; CORTICOSTEROID; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; FONTOLIZUMAB; GOLIMUMAB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; PF 00547659; PLACEBO; PURINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SEMAPIMOD; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTHRALGIA; BONE PAIN; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; INCIDENCE; INFECTION; INJECTION SITE REACTION; LIVER TOXICITY; LYMPHOMA; NEUROPATHY; OPTIC NEURITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SPONDYLOARTHROPATHY; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947677726     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.1.49     Document Type: Review

References (51)

1. PODOLSKY DK: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347:417-429. • Concise review of the current concepts on the pathogenesis of IBD.
2. HUGOT JP, CHAMAILLARD M, ZOUALI H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 411:599-603. • Report on the discovery of the first susceptibility gene for Crohn's disease, CARD-15. The two independent papers come to the same conclusion, but a different methodology as used to search for an association between polymorphisms in the CARD-15 gene and Crohn's disease.
3. OGURA Y, BONEN DK, INOHARA N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 411:603-606. • Report on the discovery of the first susceptibility gene for Crohn's disease, CARD-15. The two independent papers come to the same conclusion, but a different methodology as used to search for an association between polymorphisms in the CARD-15 gene and Crohn's disease.
4. FRANCHIMONT D, VERMEIRE S, EL HOUSNI H et al.: Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut (2004) 53:987-992.
5. WEHKAMP J, FELLERMANN K, HERRLINGER KR et al.: Mechanisms of disease: defensins in gastrointestinal diseases. Nat. Clin. Pract. Gastroenterol. Hepatol. (2005) 2:406-415. • Detailed overview highlighting the role of antimicrobial defensins in protecting against the development of IBD.
6. MUNKHOLM P, LANGHOLZ E, DAVIDSEN M, BINDER V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 35:360-362.
7. TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. (1997) 337:1029-1035.
8. HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541-1549.
9. PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. (1999) 340:1398-1405.
10. SANDS BE, ANDERSON FH, BERNSTEIN CN et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. (2004) 350(9):876-885.
11. BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. (2003) 348:601-608. • First large-scale analysis of the immunogenicity of infliximab used in an episodic retreatment schedule. The data show that more than half of patients treated on flare with variable intervals, develop antibodies to infliximab influencing their long-term outcome.
12. FARRELL RJ, ALSAHLI M, JEEN YT et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
13. VAN ASSCHE G, PAINTEAUD G, D'HAENS G et al.: Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn's disease but may improve pharmacokinetics. Gastroenterology (2006) 130:A-142.
14. SIEMANOWSKI B, KIP K, PLEVY S, REGUEIRO M: Adjustment in infliximab dose or dosing interval in Crohn's disease. Experience from the University of Pittsburgh. Gastroenterology (2006) 130:A-142.
15. PACAULT V, BEN HRIZ F, GORNET JM et al.: Long term follow up of Crohn's disease patients treated with infliximab using an episodic strategy. Gastroenterology (2006) 130:A-655.
16. RUTGEERTS P, DIAMOND RH, BALA M et al.: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. (2006) 63(3):433-442.
17. VON ADRIAN UH, MACKAY CR: T-cell function and migration. N. Engl. J. Med. (2002) 343:1020-1034. • Concise review of the role of adhesion molecules in mammalian immunology.
18. 7 integrins and P-selectin in leukocyte rolling and adhesion in high endothelial venules of Peyer's patches. J. Immunol. (1998) 161:2449-2456.
19. BRISKIN M, WINSOR-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. (1997) 151:97-110.
20. SANDBORN WJ, COLOMBEL JF, ENNS R et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. (2005) 353(18):1912-1925. • Report on the efficacy and tolerability of natalizumab in Crohn's disease. The trial was the largest single Phase II trial ever conducted in Crohn's disease.
21. MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2003) 348:15-23.
22. YOUDIM A, VASILIAUSKAS EA, TARGAN SR et al.: A pilot study of adalimumab in infliximab-allergic patients. Infiamm. Bowel Dis. (2004) 10:333-338.
23. SANDBORN WJ, HANAUER S, LOFTUS EV Jr et al.: Open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. (2004) 99(10):1984-1989.
24. HANAUER SB, SANDBORN WB, RUTGEERTS P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-1 trial. Gastroenterology (2006) 130:323-333.
25. COLOMBEL J, SANDBORN WJ, RUTGEERTS P et al.: Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: the results of the CHARM trial. Programs and abstracts of the Digestive Disease Week. 20 - 25 May 2006, Los Angeles, CA, USA (686d).
26. SHEN C, VAN ASSCHE G, RUTGEERTS P, CEUPPENS JL: Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm. Bowel Dis. (2006) 12:22-28.
27. SHEN C, VAN ASSCHE G, COLPAERT S et al.: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. (2005) 21:251-258.
28. HWANG WYK, FOOTE J: Immunogenicity of engineered antibodies. Methods (2005) 36:3-10.
29. SCHREIBER S, RUTGEERTS P, FEDORAK RN et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 129(3):807-818.
30. SANDBORN WJ, FEAGAN BG, STOINOV S et al.: Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26 week placebo-controlled Phase III study (PRECiSe 1). Gastroenterology (2006) 130:A-107.
31. SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088-1094.
32. RUTGEERTS P, SANDBORN WJ, FEDORAK RN et al.: Onercept for moderate-to-severe Crohn's disease: a randomized, doubl-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. (2006) 4:888-893.
33. TRAVIS SP, YAP L et al.: RDP58 - a novel and effective oral therapy for ulcerative colitis (UC) results of parallel prospective, multicentre, blinded placebo-controlled trials. Gut (2003) 52(SVI):A5.
34. HOMMES D, VAN DEN BLINK B, PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology (2002) 122:7-14.
35. KLEINSCHMIDT-DEMASTERS BK, TYLER KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β1a for multiple sclerosis. N. Engl. J. Med. (2005) 353:369-374.
36. LANGER-GOULD A, ATLAS SW, GREEN AJ et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. (2005) 353:375-381.
37. VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. (2005) 353:362-368.
38. YOUSRY TA, MAJOR EO, RYSCHKEWITSCH C et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopahty. N Engl. J. Med. (2006) 354:924-933. • Post-hoc safety analysis estimating the risk of progressive multifocal leukencephalopathy in patients exposed to natalizumab, based on expert neurology reports, imaging and JC virus loads.
39. MANNON P, FUSS I, MAYER L et al.: Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. (2004) 352:2069-2079.
40. HOMMES DW, MIKHAJLOVA TL, STOINOV S et al.: Fontolizumab, a humanised anti-interferon-γ antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease. Gut (2006) 55:1138-1144.
41. REINISCH W, HOMMES DW, VAN ASSCHE G et al.: A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-γ antibody, in patients with moderate-to-severe Crohn's disease. Gut (2006) 55:1131-1137.
42. KORZENIK JR. DIECKGRAEFE BK, VALENTINE JF et al.: Sargramostim for active Crohn's disease. N. Engl. J. Med. (2005) 352:2193-201.
43. ITO H, TAKAZOE M, FUKUDA Y et al.: A pilot randomized trial of a human anti-interleukin-6 monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 126:989-996.
44. HOMMES D, BAERT F, VAN ASSCHE G et al.: The ideal management of Crohn's disease: top down vetsus step up strategies, a randomized controlled trial. Gastroenterology (2006) 130:A108 (Abstract).
45. TEN HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP, VAN DEVENTER SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 50:206-211.
46. VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124:1774-1785.
47. LUGERING A, SCHMIDT M, LUGERING N et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology (2001) 121:1145-1157.
48. DI SABATINO A, CICCOCIOPPO R, CINQUE B et al.: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut (2004) 53:70-77.
49. RINGHEANU M, DAUM F, MARKOWITZ J et al.: Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm. Bowel Dis. (2004) 10:801-810.
50. HLAVATY T, PIERIK M, HENCKAERTS L et al.: Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. (2005) 22(7):613-626.
51. LICHTENSTEIN GR, FEAGAN BG, COHEN RD et al.: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. (2006) 4:621-630.